November 6-10, 2024 | Houston, Texas

Discover G4X at SITC

Booth #913

See the data and meet our team of experts at this year’s annual meeting of the Society for Immunotherapy of Cancer (SITC) to learn how our breakthrough spatial technology can transform your cancer research.

We present the G4X Spatial Sequencer, a high-throughput in situ sequencing platform. With transcriptomic, proteomic, and fH&E analysis from FFPE samples, the G4X is a high-impact multiomic platform for cost-effective single-cell cancer research.

Schedule a Meeting
Explore G4X

Check Out The Data from SITC

Direct-Seq: In Situ Sequencing of IgH and TCRB RNA at Sub-cellular Resolution on the G4X

Abstract #186
Presented November 9

DOWNLOAD POSTER

High Resolution In-Situ Multiomic Analysis of FFPE Tissue at Scale on the G4X Spatial Sequencer

Abstract #206
Presented November 9

DOWNLOAD POSTER

Spatial Technology Access Services

Want to access tomorrow’s high-throughput in situ sequencing technology today with cost-effective subcellular spatial multiomic services for your cancer research studies? Meet our team of experts and get involved today.

LEARN MORE

Spatial Data Gallery

Review the latest data generated on the G4X Spatial Sequencer across a range of tissue types.

Multiomic Profiling of Healthy & Breast Cancer
Cell Typing, Transcriptomics, Proteomics, and fH&E

Multiomic Profiling of Healthy & Colon Cancer
Cell Typing, Transcriptomics, Proteomics, and fH&E

Multiomic Profiling of Healthy & Kidney Cancer
Cell Typing, Transcriptomics, Proteomics, and fH&E

Multiomic Profiling of Healthy & Lung Cancer
Cell Typing, Transcriptomics, Proteomics, and fH&E

Transcriptomic Analysis of Healthy & Breast Cancer

Connect with Us at SITC

Please provide your information and a member of the Singular Genomics team will be in contact to set up a meeting.

Download G4X Direct-Seq Poster

Please provide your information to access and download the poster.

Download G4X Spatial Multiomic Analysis Poster

Please provide your information to access and download the poster.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Drew Spaventa

Max Reads Application Note